Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Moderna

What happened to the AstraZeneca vaccine? How blood clot scares tarnished its reputation

While the AZ./Oxford vaccine has all but vanished from richer countries, it has continued to be rolled out elsewhere

Wales Online

China's bet on homegrown mRNA vaccines holds back nation

China is trying to navigate its biggest coronavirus outbreak without a tool it could have adopted many months ago, the kind of vaccines that have proven to offer the best protection against the worst outcomes from COVID-19

The Independent UK

Here's How Much You Would Have Made Owning Moderna Stock In The Last 5 Years

Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 102.55% on an annualized basis producing an average annual return of 112.95%. Currently, Moderna has a market capitalization of $54.60 billion.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

What's next for COVID-19 vaccines for youngest US children

Parents hoping to get their youngest children vaccinated against COVID-19 have some encouraging news

The Independent UK

Looking At Moderna's Recent Whale Trades

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Pfizer, BioNTech Say Three-Dose Covid Vaccine Is 80% Effective In Children Under 5

Vaccine stocks edged higher Monday after Pfizer said its three-dose Covid vaccine was more than 80% effective in toddlers and infants.

Investors Business Daily

Pfizer says 3 COVID shots protect children under 5

Pfizer says three small doses of its COVID-19 vaccine protect kids under 5 and that it plans to give the data to U.S. regulators later this week

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Moderna Soars Following FDA Comments On COVID-19 Vaccine For Kids Under 5: What's Next?

Moderna, Inc (NASDAQ: MRNA) was spiking higher on Thursday, holding up better than the general markets, which saw the S&P 500 rally over 1% off the open before giving it all back.

Benzinga

The Daily Biotech Pulse: Pfizer/BioNTech's COVID-19 Booster For Kids, Moderna Starts First African Trial Of mRNA HIV Vaccine, Tonix Extends COVID-19 Antiviral Research Pact

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Morning Brief: Top Financial Stories Dominating on Wednesday, May 18

CNBC Toyota Looks To Develop Hydrogen Mobility In Europe

Benzinga

Moderna's Chairman Defends Executive Hiring Process After Firing New CFO In Just One Day

Moderna Inc’s (NASDAQ: MRNA) chairman comes forward with a determined defense of the board’s executive hiring process after being forced to fire its new chief financial officer just a day after taking charge.

Benzinga

India’s ‘other’ COVID vaccines: The status of under-trial, approved and unused jabs

While Covishield and Covaxin lead the Covid-19 vaccination effort in India, other vaccines, too, are under development or remain unused after approval from the Centre

The Hindu

Vic institute to tackle neglected diseases

Victoria's Burnet Institute has partnered with Moderna to develop new vaccines for diseases such as malaria and hepatitis C.

AAP

Here's How Much $1000 Invested In Moderna 5 Years Ago Would Be Worth Today

Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 105.44% on an annualized basis producing an average annual return of 116.6%. Currently, Moderna has a market capitalization of $56.68 billion.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Moderna And 3 Other Stocks Insiders Are Selling

US crude oil futures traded lower, dropping around 0.5% on Monday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

Morning Brief: Top Financial Stories Dominating on Monday, May 16

CNBC Volkswagen CEO Shares Ambitious EV Ambitions For US Market

Investors Business Daily

How Long It'll Take 10 Crushed Stocks Like Netflix To Rebound

Waiting for Netflix and other fallen S&P 500 stocks to bounce back from their epic crashes? Hope you have a big bag of popcorn and lots of time to wait — like four years.

The Conversation

Australia risks relying on Pfizer and Moderna for its COVID vaccines. 3 ways to break free

The rapid development and deployment of COVID vaccines has been one of the greatest achievements of the pandemic.

Get all your
news in one place.

100’s of premium titles.
One news app.

Axios

Biden administration and GOP clash over vaccine strategy

The administration wants to keep access as open as possible, but the GOP wants to reduce wastage.

Benzinga

Why Did Moderna CFO Exit Just A Day After Taking Charge

Moderna Inc (NASDAQ:MRNA) announced that its recently appointed Chief Financial Officer, Jorge Gomez, has departed the company, effective immediately. The announcement follows the public disclosure by Gomez's former employer, Dentsply Sirona Inc (NASDAQ:XRAY), of an ongoing internal investigation into some issues, including financial reporting. The audit investigates Dentsply Sirona's "use of incentives to sell products to…

Benzinga

Why Moderna Shares Are Trading Lower Following Novavax's Earnings Report

Moderna Inc (NASDAQ: MRNA) shares are trading lower by 3.15% at $131.52.

Daily Record

Fourth Covid booster vaccine 'significantly' improves protection over just three jabs

It is "over and above" the level of protection that people who have had their third jab receive, according to the latest research.

The Guardian - UK

Covid vaccines safe for pregnant women and cut stillbirth risk, says review

Chance of stillbirth reduced by 15%, researchers find, after examining studies and trials that enrolled 117,552 women

Wales Online

Fourth booster ‘significantly’ increases Covid protection

Levels of antibodies waned in period between third jabs and fourth boosters

The Independent UK

Covid: ‘Vaccine ceiling’ approaching for some as study suggests fourth jab may not be necessary

A ‘hint’ that some people might have already reached ‘ceiling’ in terms of protection they could acquire from fourth jab

1 … 26 27 28 29

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Intellectual Property

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.